The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones

Journal of Medicinal Chemistry

Volumn 39, Issue 3, 1996, Pages 665-668

  Willson, Timothy M ^a   Cobb, Jeffery E ^a   Cowan, David J ^a   Wiethe, Robert W ^a   Correa, Itzela D ^a   Prakash, Shimoga R ^a   Beck, Kelli D ^a   Moore, Linda B ^a   Kliewer, Steven A ^a   Lehmann, Jürgen M ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIGLITAZONE; CLOFIBRATE; ENGLITAZONE; PEROXISOME PROLIFERATOR; PIOGLITAZONE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE;

ARTICLE; DOSE RESPONSE; GLUCOSE UTILIZATION; INSULIN RESISTANCE; LIGAND BINDING; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; HYPOGLYCEMIC AGENTS; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TRANSCRIPTION FACTORS;

EID: 0030062325     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950395a     Document Type: Article

References (32)

1. Ferrannini, E. The Insulin Resistance Syndrome. Curr. Opin. Nephrol. Hypertens. 1992, 1, 291-298.
2. (a) Warram, J. H.; Martin, B. C.; Krolewski, A. S.; Soeldner, J. S.; Kahn, C. R. Slow Glucose Removal Rate and Hyperinsulinemia Precede the Development of Type II Diabetes in the Offspring of Diabetic Parents. Ann. Intern. Med. 1990, 113, 909-915.
3. (b) Lillioja, S.; Mott, D. M.; Spraul, M.; Ferraro, R.; Foley, J. E.; Ravussin, E.; Knowler, W. C.; Bennett, P. H.; Bogardus C. Insulin Resistance and Insulin Secretory Dysfunction as Precursors of Non-Insulin-Dependent Diabetes Mellitus: Prospective Studies of Pima Indians. N. Engl. J. Med. 1993, 329, 1988-1992.
4. Colca, J. R.; Tanis, S. P. Recent Advances in the Discovery and Development of Potential Antidiabetic Agents. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press Inc.: San Diego, 1992; Vol. 27, pp 219-226.
5. (a) Fujita, T.; Sugiyama, Y.; Taketomi, S.; Sohda, T.; Kawamatsu, Y.; Iwatsuka, H.; Suzjoka, Z. Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent Diabetes 1983, 32, 804-810.
6. (b) Chang, A. Y.; Wyse, B. M.; Gilchrist, B. J.; Peterson, T.; Diani, A. R. Ciglitazone, a New Hypoglycemic Agent. Diabetes 1983, 32, 830-838.
7. (c) Sugiyama, Y.; Taketomi, S.; Shimara, Y.; Ikeda, H.; Fujita, T. Effects of Pioglitazone on Glucose and Lipid Metabolism in Wistar Fatty Rats. Arzneim. Forsch./Drug Res. 1990, 40, 263-267.
8. (d) Stevenson, R. W., Hutson, N. J.; Krapp, M. N.; Volkmann, R. A.; Holland, G. F.; Eggler, J. F.; Clark, D. A.; McPherson, R. K.; Hall, K. L.; Danbury, B. H.; Gibbs, E. M.; Krentler, D. K.; Actions of Novel Antidiabetic Agent Englitazone in Hyperglycemic Hyperinsulinemic ob/ob Mice. Diabetes 1990, 39, 1218-1227.
9. Nolan, J. J.; Ludvik, B.; Beerdsen, P.; Joyce, M.; Olefsky, J. Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone. N. Engl. J. Med. 1994, 331, 1188-1193.
10. (a) Ferrari, C.; Testori, G. P.; Betazzoni, A.; Romussi, M.; Caldara, R.; Frezzati, S. Increased Glucose Disappearance Rate after Short-term Clofibrate Administration in Normal Subjects and in Patients with Chemical Diabetes. Horm. Metab. Res. 1978, 10, 4-6.
11. (b) Barnett, D.; Craig, J. G., Robinson, D. S.; Perenna Rogers, M. Effect of Clofibrate on Glucose Tolerance in Maturity Onset Diabetes. Br. J. Clin. Pharmacol. 1977, 4, 455-458.
12. (a) Kawamatsu, Y.; Saraie, T.; Imamiya, E.; Nishikawa, K.; Hamuro, Y. Studies on Antihyperlipidemic Agents. Arzneim.-Forsch./Drug Res. 1980, 30, 454-459.
13. (b) Sohda, T.; Mizuno, K.; Imamiya, E.; Sugiyama, Y.; Fujita, T.; Kawamatsu, Y. Studies on Antidiabetic Agents. II. Synthesis of 5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878) and its Derivatives. Chem. Pharm. Bull. 1982, 30, 3580-3600.
14. Hulin, B. New Hypoglycemic Agents. Prog. Med. Chem. 1994, 31, 1-58.
15. Shoda, T.; Momose, Y.; Meguro, K.; Kawamatsu, Y.; Sugiyama, Y.; Ikeda, H. Studies on Antidiabetic Agents: Synthesis and Hypoglycemic Actvity of 5-[4-(Pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneim.-Forsch./Drug Res. 1990, 40, 37-42.
16. (a) Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [[ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents, J. Med. Chem. 1994, 37, 3977-3985.
17. (b) Cantello, B. C. C.; Cawthorne, M. A.; Haigh, D.; Hindley, R. M.; Smith, S. A.; Thurlby, P. L. The Synthesis of BRL 49653 - a Novel and Potent Antihyperglycemic Agent. Bioorg. Med. Chem. Lett. 1994, 10, 1181-1184.
18. Clark, D. A.; Goldstein, S. W.; Volkmann, R. A.; Eggler, J. F.; Holland, G. F.; Hulin, B.; Stevenson, R. W.; Kreutter, D. K.; Michael Gibbs, E.; Krupp, M. N.; Merrigan, P.; Kelbaugh, P. L.; Andrews, E. G.; Tickner, D. L.; Suleske, R. T.; Lamphere, C. H.; Rajeckas, F. J.; Kappeler, W. H.; McDermott, R. E.; Hutson, N. J.; Johnson, M. R. Substituted Dihydrobenzopyran and Dihydrobenzofuran Thiazolidine-2,4-diones as Hypoglycemic Agents. J. Med. Chem. 1991, 34, 319-325.
19. (a) Isseman, I.; Green, S. Activation of a Member of the Steroid Hormone Receptor Superfamily by Peroxisome Proliferates. Nature 1990, 347, 645-650.
20. (b) Schmidt, A.; Endo, N.; Rutledge, S. J.; Vogel, R.; Shinar, D.; Rodan, G. A. Identification of a New Member of the Steroid Hormone Receptor Superfamily that is Activated by a Peroxisome Proliferator and Fatty Acids. Mol. Endocrinol. 1992, 6, 1634-41.
21. (c) Kliewer, S. A.; Forman, B. M.; Blumberg, B.; Ong, E. S.; Borgmeyer, U.; Manglesdorf, D. J.; Umesono, K.; Evans, R. M. Differential Expression and Activation of a Family of Murine Peroxisome Proliferator-activated Receptors. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 7355-7359.
22. Desvergne, B.; Wahli, W. PPAR: a Key Nuclear Factor in Nutrient/Gene Interactions? In Inducible Gene Expression; Baeuerle, P., Ed.; Birkhause: Boston, 1995; pp 142-176.
23. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor γ (PPARγ). J. Biol. Chem. 1995, 270, 12953-12956.
24. Thorpe, J. M. Experimental Evaluation of an Orally Active Combination of Andosterone and Ethyl Chlorophenoxy-isobutryrate. Lancet 1962, 1323-1326.
25. 50 ∼10 μM: Ibrahimi, A.; Teboul, L; Gaillard, D; Amri, E.-Z.; Ailhaud, G.; Young, P.; Cawthorne, M. A.; Grimaldi, P. A. Evidence for a Common Mechanism of Action for Fatty Acids and Thiazolidinedione Antidiabetic Agents on Gene Expression in Preadipose Cells. Mol. Pharmacol. 1994, 46, 1070-1076.
26. 2 = 0.91, P < 0.0005.
27. A reviewer has noted that a number of structurally diverse thiazolidinediones of varying potencies exist which were not included in our analysis. Therefore caution should be exercised in extending our results to cover these other classes of compounds.
28. Chawla, A.; Schwarz, E. J.; Dimaculangan, D. D.; Lazar, M. A. Peroxisome Proliferator-activated Receptor (PPAR) γ: Adipose-predominant Expression and Induction Early in Adipose Differentiation. Endocrinology 1994, 135, 798-800.
29. Tontonoz, P.; Hu, E.; Spiegelman, B. M. Stimulation of Adipogenesis in Fibroblasts by PPARγ2, a Lipid-activated Transcription Factor. Cell 1994, 79, 1-20.
30. Flier, J. S. The Adipocyte: Storage Depot or Node on the Energy Information Superhighway? Cell 1995, 80, 15-18.
31. Berger, J.; Hauber, R.; Geiger, R.; Cullen, B. R. Secreted Alkaline Phosphatase: a Powerful New Quantitative Indicator of Gene Expression in Eukaryotic Cells. Gene 1988, 66, 1-10.
32. Pfahl, M; Tzuckerman, M; Zhang, X.-K.; Lehmann, J. M.; Hermann, T.; Wills, K. N.; Graupner, G. Nuclear Retinoic Acid Receptors: Cloning, Analysis, and Function. Methods Enzymol. 1990, 26, 256-270.